sarpogrelate has been researched along with Disease Models, Animal in 22 studies
sarpogrelate: structure given in first source
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study was designed to examine the impact of combined multipotent adipose-derived stromal cells (mADSCs) and sarpogrelate treatment on aging hindlimb ischemia and the mechanism of action involved." | 7.79 | Adipose stromal cell and sarpogrelate orchestrate the recovery of inflammation-induced angiogenesis in aged hindlimb ischemic mice. ( Bu, Q; Cao, F; Cheng, K; Da, H; Fan, W; Han, Y; Li, C; Li, X; Qin, X; Ren, J; Tong, C; Wang, S; Zhou, R, 2013) |
| " The present study investigates the effects of a 5-HT(2A) receptor antagonist, sarpogrelate on endotoxin shock." | 7.75 | Acute effects of sarpogrelate, a 5-HT2A receptor antagonist on cytokine production in endotoxin shock model of rats. ( Nishiyama, T, 2009) |
| "The effectiveness of sustained-release basic fibroblast growth factor (bFGF) in potentiating arteriogenesis and angiogenesis was evaluated, as well as determining whether chronic oral administration of sarpogrelate, a serotonin blocker, would further increase collateral blood flow in the rabbit hindlimb following surgical induction of ischemia by femoral artery extraction." | 7.73 | Combined treatment of sustained-release basic fibroblast growth factor and sarpogrelate enhances collateral blood flow effectively in rabbit hindlimb ischemia. ( Arai, Y; Chandra, S; Fujita, M; Hirose, K; Huang, Y; Komeda, M; Marui, A; Sakaguchi, H; Tabata, Y, 2006) |
| " Acute and chronic effects of sarpogrelate hydrochloride (sarpogrelate), a 5-HT2 blocker, on glucose tolerance and insulin resistance were examined." | 7.72 | Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model. ( Harada, N; Nakaya, Y; Takahashi, A; Takishita, E; Yamato, M; Yoshizumi, M, 2004) |
| " This study examined the effect of sarpogrelate, a 5-HT(2A) receptor blocker, in preventing cardiac dysfunction due to myocardial infarction (MI)." | 7.71 | Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats. ( Brasil, D; Dhalla, NS; Kumamoto, H; Kumar, K; Takeda, N; Temsah, RM, 2002) |
| " This study was designed to examine the impact of combined multipotent adipose-derived stromal cells (mADSCs) and sarpogrelate treatment on aging hindlimb ischemia and the mechanism of action involved." | 3.79 | Adipose stromal cell and sarpogrelate orchestrate the recovery of inflammation-induced angiogenesis in aged hindlimb ischemic mice. ( Bu, Q; Cao, F; Cheng, K; Da, H; Fan, W; Han, Y; Li, C; Li, X; Qin, X; Ren, J; Tong, C; Wang, S; Zhou, R, 2013) |
| " The present study investigates the effects of a 5-HT(2A) receptor antagonist, sarpogrelate on endotoxin shock." | 3.75 | Acute effects of sarpogrelate, a 5-HT2A receptor antagonist on cytokine production in endotoxin shock model of rats. ( Nishiyama, T, 2009) |
| "The effectiveness of sustained-release basic fibroblast growth factor (bFGF) in potentiating arteriogenesis and angiogenesis was evaluated, as well as determining whether chronic oral administration of sarpogrelate, a serotonin blocker, would further increase collateral blood flow in the rabbit hindlimb following surgical induction of ischemia by femoral artery extraction." | 3.73 | Combined treatment of sustained-release basic fibroblast growth factor and sarpogrelate enhances collateral blood flow effectively in rabbit hindlimb ischemia. ( Arai, Y; Chandra, S; Fujita, M; Hirose, K; Huang, Y; Komeda, M; Marui, A; Sakaguchi, H; Tabata, Y, 2006) |
| " Acute and chronic effects of sarpogrelate hydrochloride (sarpogrelate), a 5-HT2 blocker, on glucose tolerance and insulin resistance were examined." | 3.72 | Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model. ( Harada, N; Nakaya, Y; Takahashi, A; Takishita, E; Yamato, M; Yoshizumi, M, 2004) |
| " This study examined the effect of sarpogrelate, a 5-HT(2A) receptor blocker, in preventing cardiac dysfunction due to myocardial infarction (MI)." | 3.71 | Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats. ( Brasil, D; Dhalla, NS; Kumamoto, H; Kumar, K; Takeda, N; Temsah, RM, 2002) |
| "Nonalcoholic fatty liver disease (NAFLD) is increasing in worldwide prevalence, closely tracking the obesity epidemic, but specific pharmaceutical treatments for NAFLD are lacking." | 1.48 | Serotonin signals through a gut-liver axis to regulate hepatic steatosis. ( Bang, G; Choi, C; Choi, W; Han, KH; Hwang, I; Jeong, JS; Ju, YS; Karsenty, G; Kim, H; Kim, YH; Lee, HW; Lim, A; Namkung, J; Park, HJ; Park, JY; Park, S; Suh, JM; Yadav, VK, 2018) |
| "BALB/c mice were dosed intraperitoneally with 5, 15, 30, 40, or 50 mg/kg sarpogrelate 48, 24, and 0 hours prior to bright light exposure (10,000 lux) as well as 24 and 48 hours after exposure." | 1.42 | Sarpogrelate, a 5-HT2A Receptor Antagonist, Protects the Retina From Light-Induced Retinopathy. ( Coyner, AS; Datta, S; Gale, MJ; Ku, C; Nicholson, A; Pennesi, ME; Regis, D; Ryals, RC; Sinha, W; Tullis, BE; Wen, Y; Yang, P, 2015) |
| "When isosorbide dinitrate (ISDN, 1 mM) was applied during isometric measurement, 18." | 1.31 | The effects of vasodilators on the relaxation of guinea-pig aorta during acute recoil. ( Hirai, M; Iino, S; Kondo, T; Takeshita, K; Tanaka, T, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 15 (68.18) | 29.6817 |
| 2010's | 4 (18.18) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Kim, SK | 1 |
| Kim, G | 1 |
| Choi, BH | 1 |
| Ryu, D | 1 |
| Ku, SK | 1 |
| Kwak, MK | 1 |
| Choi, W | 1 |
| Namkung, J | 1 |
| Hwang, I | 1 |
| Kim, H | 2 |
| Lim, A | 1 |
| Park, HJ | 1 |
| Lee, HW | 1 |
| Han, KH | 1 |
| Park, S | 2 |
| Jeong, JS | 1 |
| Bang, G | 1 |
| Kim, YH | 1 |
| Yadav, VK | 1 |
| Karsenty, G | 1 |
| Ju, YS | 1 |
| Choi, C | 1 |
| Suh, JM | 1 |
| Park, JY | 1 |
| Hamasaki, Y | 1 |
| Doi, K | 1 |
| Maeda-Mamiya, R | 1 |
| Ogasawara, E | 1 |
| Katagiri, D | 1 |
| Tanaka, T | 2 |
| Yamamoto, T | 1 |
| Sugaya, T | 1 |
| Nangaku, M | 1 |
| Noiri, E | 1 |
| Tullis, BE | 1 |
| Ryals, RC | 1 |
| Coyner, AS | 1 |
| Gale, MJ | 1 |
| Nicholson, A | 1 |
| Ku, C | 1 |
| Regis, D | 1 |
| Sinha, W | 1 |
| Datta, S | 1 |
| Wen, Y | 1 |
| Yang, P | 1 |
| Pennesi, ME | 1 |
| Barta, J | 2 |
| Sanganalmath, SK | 2 |
| Kumamoto, H | 3 |
| Takeda, N | 3 |
| Edes, I | 1 |
| Dhalla, NS | 3 |
| Nishiyama, T | 1 |
| Iizuka, K | 1 |
| Hamaue, N | 1 |
| Machida, T | 1 |
| Hirafuji, M | 1 |
| Tsuji, M | 1 |
| Fan, W | 1 |
| Li, C | 2 |
| Qin, X | 1 |
| Wang, S | 1 |
| Da, H | 1 |
| Cheng, K | 1 |
| Zhou, R | 1 |
| Tong, C | 1 |
| Li, X | 1 |
| Bu, Q | 1 |
| Han, Y | 1 |
| Ren, J | 1 |
| Cao, F | 1 |
| Okamoto, K | 1 |
| Imbe, H | 1 |
| Morikawa, Y | 1 |
| Itoh, M | 1 |
| Sekimoto, M | 1 |
| Nemoto, K | 1 |
| Senba, E | 1 |
| Shimizu, Y | 1 |
| Minatoguchi, S | 1 |
| Hashimoto, K | 1 |
| Uno, Y | 1 |
| Arai, M | 1 |
| Wang, N | 1 |
| Chen, X | 1 |
| Lu, C | 1 |
| Takemura, G | 1 |
| Shimomura, M | 1 |
| Fujiwara, T | 1 |
| Fujiwara, H | 1 |
| Iino, S | 1 |
| Takeshita, K | 1 |
| Kondo, T | 1 |
| Hirai, M | 1 |
| Hayashi, T | 1 |
| Sumi, D | 1 |
| Matsui-Hirai, H | 1 |
| Fukatsu, A | 1 |
| Arockia Rani P, J | 1 |
| Kano, H | 1 |
| Tsunekawa, T | 1 |
| Iguchi, A | 1 |
| Takishita, E | 1 |
| Takahashi, A | 1 |
| Harada, N | 1 |
| Yamato, M | 1 |
| Yoshizumi, M | 1 |
| Nakaya, Y | 1 |
| Nitanda, A | 1 |
| Yasunami, N | 1 |
| Tokumo, K | 1 |
| Fujii, H | 1 |
| Hirai, T | 1 |
| Nishio, H | 1 |
| Nishihira, K | 1 |
| Yamashita, A | 1 |
| Tanaka, N | 1 |
| Kawamoto, R | 1 |
| Imamura, T | 1 |
| Yamamoto, R | 1 |
| Eto, T | 1 |
| Asada, Y | 1 |
| Hirose, K | 1 |
| Fujita, M | 1 |
| Marui, A | 1 |
| Arai, Y | 1 |
| Sakaguchi, H | 1 |
| Huang, Y | 1 |
| Chandra, S | 1 |
| Tabata, Y | 1 |
| Komeda, M | 1 |
| Sekiguchi, M | 1 |
| Konno, S | 1 |
| Kikuchi, S | 1 |
| Origuchi, N | 1 |
| Shigematsu, H | 1 |
| Muto, T | 1 |
| Miyata, K | 1 |
| Shimokawa, H | 1 |
| Higo, T | 1 |
| Yamawaki, T | 1 |
| Katsumata, N | 1 |
| Kandabashi, T | 1 |
| Tanaka, E | 1 |
| Takamura, Y | 1 |
| Yogo, K | 1 |
| Egashira, K | 1 |
| Takeshita, A | 1 |
| Brasil, D | 1 |
| Temsah, RM | 1 |
| Kumar, K | 1 |
22 other studies available for sarpogrelate and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Negative correlation of urinary miR-199a-3p level with ameliorating effects of sarpogrelate and cilostazol in hypertensive diabetic nephropathy.
Topics: Animals; Biomarkers, Pharmacological; Cilostazol; Diabetic Nephropathies; Disease Models, Animal; Hy | 2021 |
Serotonin signals through a gut-liver axis to regulate hepatic steatosis.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulati | 2018 |
A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1.
Topics: Adenine; Animals; Cells, Cultured; Disease Models, Animal; Fatty Acid-Binding Proteins; Fibrosis; In | 2013 |
Sarpogrelate, a 5-HT2A Receptor Antagonist, Protects the Retina From Light-Induced Retinopathy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Disease Models, Animal; Electroretinography; Inject | 2015 |
Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cilostazol; Coronary Occlusion; Cyclic AMP; D | 2008 |
Acute effects of sarpogrelate, a 5-HT2A receptor antagonist on cytokine production in endotoxin shock model of rats.
Topics: Animals; Cytokines; Disease Models, Animal; Hemodynamics; Lung; Male; Rats; Rats, Sprague-Dawley; Re | 2009 |
Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice.
Topics: Abdominal Fat; Adipocytes; Animals; Blood Glucose; Cell Count; Diabetes Mellitus, Type 2; Disease Mo | 2009 |
Adipose stromal cell and sarpogrelate orchestrate the recovery of inflammation-induced angiogenesis in aged hindlimb ischemic mice.
Topics: Adipose Tissue; Aging; Angiogenesis Inducing Agents; Animals; Disease Models, Animal; Hindlimb; Infl | 2013 |
5-HT2A receptor subtype in the peripheral branch of sensory fibers is involved in the potentiation of inflammatory pain in rats.
Topics: Animals; Behavior, Animal; Calcitonin Gene-Related Peptide; Chronic Disease; Disease Models, Animal; | 2002 |
The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts.
Topics: Adenosine Triphosphate; Alkaloids; Animals; Benzophenanthridines; Decanoic Acids; Disease Models, An | 2002 |
The effects of vasodilators on the relaxation of guinea-pig aorta during acute recoil.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angioplasty, Balloon, Coronary; Animals; Aorta, Thoracic; | 2002 |
Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism.
Topics: Acetylcholine; Animals; Antioxidants; Aorta, Thoracic; Biomarkers; Blood Proteins; Cholesterol, HDL; | 2003 |
Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Insulin Resistan | 2004 |
Contribution of the peripheral 5-HT 2A receptor to mechanical hyperalgesia in a rat model of neuropathic pain.
Topics: Animals; Binding Sites; Binding, Competitive; Denervation; Disease Models, Animal; Drug Interactions | 2005 |
Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery.
Topics: Animals; Arterial Occlusive Diseases; Catheterization; Disease Models, Animal; Femoral Artery; Fibri | 2006 |
Combined treatment of sustained-release basic fibroblast growth factor and sarpogrelate enhances collateral blood flow effectively in rabbit hindlimb ischemia.
Topics: Animals; Collateral Circulation; Disease Models, Animal; Drug Combinations; Fibrinolytic Agents; Fib | 2006 |
The effects of a 5-HT2A receptor antagonist on blood flow in lumbar disc herniation: application of nucleus pulposus in a canine model.
Topics: Animals; Blood Vessels; Disease Models, Animal; Dogs; Female; Intervertebral Disc; Intervertebral Di | 2008 |
Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Cilostazol; Disease Models, Animal; Echocardiography; Electrocardiogr | 2008 |
Anplag, a selective 5-HT2 receptor antagonist, reduces stenosis induced by balloon injury in the hypercholesterolaemic rabbit.
Topics: Administration, Oral; Angioplasty, Balloon; Animals; Carotid Artery Injuries; Carotid Artery, Common | 1997 |
Sarpogrelate, a selective 5-HT2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model.
Topics: Angiography; Animals; Base Sequence; Coronary Vasospasm; Dinoprost; Disease Models, Animal; Dose-Res | 2000 |
Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats.
Topics: Animals; Disease Models, Animal; Electrocardiography; Heart; Heart Conduction System; Male; Myocardi | 2002 |